Cover Image
市場調查報告書

嗜酸性粒細胞性食道炎:開發平台分析

Eosinophilic Esophagitis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 246006
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
嗜酸性粒細胞性食道炎:開發平台分析 Eosinophilic Esophagitis - Pipeline Review, H2 2016
出版日期: 2016年10月19日 內容資訊: 英文 68 Pages
簡介

所謂的嗜酸性粒細胞性食道炎是反應食物·過敏原·吞酸等之嗜酸性粒細胞(白血球的一種)積蓄在食道組織內的症狀。主要的症狀有體重減輕和腹痛,噁心·嘔吐,咳嗽,胃灼熱,胸部疼痛等。致病因素有伴隨HIV/AIDS感染的免疫系統衰弱化,及糖尿病,白血病,淋巴瘤,其他自體免疫疾病,化療,阿斯匹林劑·抗發炎劑,慢性嘔吐,肥胖,飲酒,抽煙等。主要的治療方法包含有抗病毒藥物,抗真菌藥物,止痛藥等。

本報告提供全球各國治療嗜酸性粒細胞性食道炎用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

嗜酸性粒細胞性食道炎概要

治療藥的開發

  • 嗜酸性粒細胞性食道炎開發中產品:概要
  • 嗜酸性粒細胞性食道炎開發中產品:比較分析

各企業正在開發的嗜酸性粒細胞性食道炎治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

嗜酸性粒細胞性食道炎治療藥:開發中的產品一覽(各企業)

嗜酸性粒細胞性食道炎治療藥的開發企業

  • Allergan Plc
  • DBV Technologies S.A.
  • Dr. Falk Pharma GmbH
  • Novartis AG
  • Receptos, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Shire Plc

嗜酸性粒細胞性食道炎:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • Allergen for Milk Allergy
  • budesonide
  • budesonide
  • dectrekumab
  • dupilumab
  • EUR-1100
  • Qi-406
  • RPC-4046

嗜酸性粒細胞性食道炎治療藥:開發中產品的最新趨勢

嗜酸性粒細胞性食道炎治療藥:開發暫停的產品

嗜酸性粒細胞性食道炎相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8557IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides an overview of the Eosinophilic Esophagitis (Gastrointestinal) pipeline landscape.

Eosinophilic esophagitis is disease characterized by the presence of a large number of a special type of white blood cell, the eosinophil that can cause inflammation in the esophagus. Symptoms include poor weight gain, abdominal pain, nausea, and vomiting, coughing, heartburn and chest pain. Risk factors include weakened immune system, chemotherapy, aspirin and anti-inflammatory medications, chronic vomiting, obesity and alcohol and cigarette use. Treatment includes antiviral, antifungal and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Eosinophilic Esophagitis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Eosinophilic Esophagitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Eosinophilic Esophagitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 3 respectively for Eosinophilic Esophagitis.

Eosinophilic Esophagitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Eosinophilic Esophagitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Eosinophilic Esophagitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Eosinophilic Esophagitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Eosinophilic Esophagitis (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Eosinophilic Esophagitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Eosinophilic Esophagitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Eosinophilic Esophagitis Overview
  • Therapeutics Development
    • Pipeline Products for Eosinophilic Esophagitis - Overview
  • Eosinophilic Esophagitis - Therapeutics under Development by Companies
  • Eosinophilic Esophagitis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Eosinophilic Esophagitis - Products under Development by Companies
  • Eosinophilic Esophagitis - Companies Involved in Therapeutics Development
    • Adare Pharmaceuticals, Inc.
    • Calypso Biotech SA
    • Celgene Corporation
    • DBV Technologies S.A.
    • Dr. Falk Pharma GmbH
    • Novartis AG
    • Panmira Pharmaceuticals, LLC.
    • Quorum Innovations LLC
    • Regeneron Pharmaceuticals Inc
    • Shire Plc
  • Eosinophilic Esophagitis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Allergen for Milk Allergy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-461 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • budesonide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CALY-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dectrekumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qi-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RPC-4046 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Eosinophilic Esophagitis - Dormant Projects
  • Eosinophilic Esophagitis - Product Development Milestones
    • Featured News & Press Releases
      • Sep 21, 2016: DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cows Milk Protein Allergy
      • Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP621 for Rare Gastrointestinal Conditions
      • Nov 12, 2015: DBV Technologies Announces Enrollment of First Patient in Phase IIA Study in Pediatric Eosinophilic Esophagitis
      • Jul 08, 2015: IND Acceptance from FDA for a proof-of-concept trial using Viaskin Milk in Milk-Induced Eosinophilic Esophagitis in Children
      • Oct 03, 2014: Receptos Announces First Patient Treated With Anti-Interleukin-13 Antibody in Phase 2 Trial for Eosinophilic Esophagitis
      • Sep 25, 2014: Meritage Pharma Announces Positive Results of Oral Budesonide Suspension for Treatment of Eosinophilic Esophagitis in Adolescent and Adult Patients
      • Jul 21, 2014: High-dose fluticasone effective against eosinophilic esophagitis
      • May 13, 2014: DBV Technologies Announces Clinical Trial Agreement to Develop a Treatment for Milk-Induced Eosinophilic Esophagitis in Children
      • Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis
      • May 10, 2011: Meritage Pharma Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
      • May 10, 2011: Meritage Reports Positive Phase IIb Data For Oral Budesonide Suspension In Pediatric Patients With Eosinophilic Esophagitis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Eosinophilic Esophagitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Adare Pharmaceuticals, Inc., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Calypso Biotech SA, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Celgene Corporation, H2 2016
  • Eosinophilic Esophagitis - Pipeline by DBV Technologies S.A., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Novartis AG, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Panmira Pharmaceuticals, LLC., H2 2016
  • Eosinophilic Esophagitis - Pipeline by Quorum Innovations LLC, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016
  • Eosinophilic Esophagitis - Pipeline by Shire Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Eosinophilic Esophagitis - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Eosinophilic Esophagitis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top